Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002639 · ClinicalTrials.gov registry record · Phase 2

Suramin in Treating Patients With Recurrent Primary Brain Tumors

A Phase 2 study, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase

NCT00002639: Completed Phase 2 study, sponsored by Emory University.

NCT00002639 is a Phase 2 study that has completed, run by Emory University. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002639, a Phase 2 study, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.

Interventions

  • DRUG chemotherapy
  • DRUG suramin

Trial Details

FieldValue
Start Date 1995-07
Est. Completion 2004-05
Phase Phase 2
Emory University

1,208 total trials

What the finished NCT00002639 record still lists

NCT00002639 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.

NCT00002639 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002639 about?

NCT00002639 is a clinical study titled "Suramin in Treating Patients With Recurrent Primary Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.

What is the current status of trial NCT00002639?

This trial is currently completed. It is a Phase 2 study. The study started on 1995-07. Estimated completion is 2004-05.

What interventions are being tested in trial NCT00002639?

The interventions under investigation include: chemotherapy (DRUG), suramin (DRUG).

Who is sponsoring clinical trial NCT00002639?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002639, the US trial registry maintained by the National Library of Medicine. NCT00002639 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.